Wall Street took notice, and the stock more than doubled in a single session, igniting fresh interest in this under-the-radar biotech. Wall Street was not just impressed, it was outright bullish.

Invivyd (IVVD) announced a strategic partnership with professional football coach Jim Harbaugh to raise awareness about the ongoing short and ...

Teaming up to raise awareness of the continuing toll of COVID-19 in America, an ongoing mass disabling event causing an American death approximately every 9 minutes with over 59,0 ...

Invivyd, Inc. is a microcap biotech company focusing on antibody-based treatments for infectious diseases like COVID-19.

H.C. Wainwright reaffirmed its Buy rating and $10.00 price target for Invivyd Inc. (NASDAQ:IVVD), following a series of positive developments for the biotechnology company. The stock, currently ...

The stock is trading at 1.0150, up 0.6573, gaining 183.7573% on volume of over 422 Million shares, with a day's high of $1.11. The stock announced breaking news on its Monoclonal Antibody designed to ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

Invivyd data shows strong potency and prolonged antibody levels in trials. Q4 Pemgarda revenue rose 48% to $13.8 million.

In a challenging year for Adagio Therapeutics (NASDAQ:IVVD), the biotech company's stock has tumbled to a 52-week low, reaching a price level of just $0.38. This latest dip underscores a prolonged ...

Invivyd, Inc. ( NASDAQ:IVVD ) is possibly approaching a major achievement in its business, so we would like to ...